Safety and preliminary evidence of biologic efficacy of a mammaglobin-A DNA vaccine in patients with stable metastatic breast cancer

Clinical Cancer Research

Volumn 20, Issue 23, 2014, Pages 5964-5975

  Tiriveedhi, Venkataswarup ^a,b   Tucker, Natalia ^a   Herndon, John ^a   Li, Jin ^a   Sturmoski, Mark ^a   Ellis, Matthew ^a,c   Ma, Cynthia ^a,c   Naughton, Michael ^a,c   Lockhart, A Craig ^a,c   Gao, Feng ^a,c   Fleming, Timothy ^a,c   Goedegebuure, Peter ^a,c   Mohanakumar, Thalachallour ^a,c   Gillanders, William E ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TENNESSEE STATE UNIVERSITY   (United States)

^c MO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; HLA A2 ANTIGEN; MAMMAGLOBIN A; TRASTUZUMAB; VALACICLOVIR; BIOLOGICAL MARKER; CANCER VACCINE; EPITOPE; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER IMMUNIZATION; CANCER PATIENT; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY ASSAY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; EVIDENCE BASED MEDICINE; FEMALE; FLOW CYTOMETRY; FLU LIKE SYNDROME; HERPES ZOSTER; HUMAN; HUMAN CELL; HUMAN TISSUE; INJECTION SITE REACTION; LABORATORY TEST; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; METASTASIS POTENTIAL; PATIENT COMPLIANCE; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; BREAST NEOPLASMS; CLINICAL TRIAL; CYTOTOXICITY; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME; VACCINATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; BREAST NEOPLASMS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; GENETIC VECTORS; HUMANS; INTERFERON-GAMMA; MALE; MAMMAGLOBIN A; MIDDLE AGED; NEOPLASM METASTASIS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VACCINES, DNA;

EID: 84918783221     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0059     Document Type: Article

References (47)

1. Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, et al. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013;2:e23803.
2. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin Infect Dis 2011;53:296-302.
3. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:54-67.
4. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994;54:16-20.
5. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/ neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000;62:245-52.
6. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-7.
7. von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Verheijen RH, Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers 2000;15:343-56.
8. Jaramillo A, Majumder K, Manna PP, Fleming TP, Doherty G, Dipersio JF, et al. Identification of HLA-A3-restricted CD8+ T cell epitopes derived from mammaglobin-A, a tumor-associated antigen of human breast cancer. Int J Cancer 2002;102:499-506.
9. Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, Hansen TH, et al. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat 2004;88:29-41.
10. Narayanan K, Jaramillo A, Benshoff ND, Campbell LG, Fleming TP, Dietz JR, et al. Response of established human breast tumors to vaccination with mammaglobin-A cDNA. J Natl Cancer Inst 2004;96:1388-96.
11. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
12. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006;8:190-8.
13. Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, Meyer MF, et al. Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat 2006;13:505-14.
14. Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005;23:7536-45.
15. Watson MA, Fleming TP. Isolation of differentially expressed sequence tags from human breast cancer. Cancer Res 1994;54:4598-602.
16. Fleming TP, Watson MA. Mammaglobin, a breast-speci fic gene, and its utility as a marker for breast cancer. Ann N Y Acad Sci 2000;923:78-89.
17. Goedegebuure PS, Watson MA, Viehl CT, Fleming TP. Mammaglobin-based strategies for treatment of breast cancer. Curr Cancer Drug Targets 2004;4:531.
18. Watson MA, Darrow C, Zimonjic DB, Popescu NC, Fleming TP. Structure and transcriptional regulation of the human mammaglobin gene, a breast cancer associated member of the uteroglobin gene family localized to chromosome 11q13. Oncogene 1998;16:817.
19. Watson MA, Fleming TP.Mammaglobin, a mammary-specificmember of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996;56:860-5.
20. Wang Z, Spaulding B, Sienko A, Liang Y, Li H, Nielsen G, et al. Mammaglobin, a valuable diagnostic marker for metastatic breast carcinoma. Int J Clin Exp Pathol 2009;2:384-9.
21. Watson MA, Dintzis S, Darrow CM, Voss LE, DiPersio J, Jensen R, et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res 1999;59:3028-31.
22. Sasaki E, Tsunoda N, Hatanaka Y, Mori N, Iwata H, Yatabe Y. Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol 2007;20:208-14.
23. Lewis GH, Subhawong AP, Nassar H, Vang R, Illei PB, Park BH, et al. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am J Clin Pathol 2011;135:587-91.
24. Luo MH, Huang YH, Ni YB, Tsang JY, Chan SK, Shao MM, et al. Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas. Hum Pathol 2013;44:1241-50.
25. Tiriveedhi V, Sarma NJ, Subramanian V, Fleming TP, Gillanders WE, Mohanakumar T. Identification of HLA-A24-restricted CD8(+) cytotoxic T-cell epitopes derived from mammaglobin-A, a human breast cancer-associated antigen. Hum Immunol 2012;73:11-6.
26. Ilias Basha H, Tiriveedhi V, Fleming TP, Gillanders WE, Mohanakumar T. Identification of immunodominant HLA-B7-restricted CD8+ cytotoxic T cell epitopes derived from mammaglobin-A expressed on human breast cancers. Breast Cancer Res Treat 2011;127:81-9.
27. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010;2010:174378.
28. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferongamma. Proc Natl Acad Sci USA 1996;93:2879-83.
29. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996;273:352-4.
30. Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 2013;8:e55571.
31. Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013;208:818-29.
32. Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004;91:688-94.
33. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008;8:108-20.
34. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008;9:776-88.
35. Tiriveedhi V, Fleming TP, Goedegebuure PS, Naughton M, Ma C, Lockhart C, et al. Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells. Breast Cancer Res Treat 2013;138:109-18.
36. Bharat A, Benshoff N, Fleming TP, Dietz JR, Gillanders WE, Mohanakumar T. Characterization of the role of CD8+T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers. Breast Cancer Res Treat 2008;110:453-63.
37. Tiriveedhi V, Gelman AE, Mohanakumar T. HIF-1alpha signaling by airway epithelial cell K-alpha1-tubulin: role in fibrosis and chronic rejection of human lung allografts. Cell Immunol 2012;273:59-66.
38. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
39. Ratner A, Clark WR. Role of TNF-alpha in CD8+ cytotoxic T lymphocyte-mediated lysis. J Immunol 1993;150:4303-14.
40. Chu T, Tyznik AJ, Roepke S, Berkley AM,Woodward-Davis A, Pattacini L, et al. Bystander-Activated memory CD8 T cells control early pathogen load in an innate-like, NKG2D-dependent manner. Cell Rep 2013;3:701-8.
41. Burgess SJ, Marusina AI, Pathmanathan I, Borrego F, Coligan JE. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J Immunol 2006;176:1490-7.
42. Kremer M, Suezer Y, Volz A, Frenz T, Majzoub M, Hanschmann KM, et al. Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox. PLoS Pathog 2012;8:e1002557.
43. O'Brien N, Maguire TM, O'Donovan N, Lynch N, Hill AD, McDermott E, et al. Mammaglobin a: a promising marker for breast cancer. Clin Chem 2002;48:1362-4.
44. Cui H, Zhang W, Hu W, Liu K, Wang T, Ma N, et al. Recombinant mammaglobin A adenovirus-infected dendritic cells induce mammaglobin A-specific CD8+ cytotoxic T lymphocytes against breast cancer cells in vitro. PLoS ONE 2013;8:e63055.
45. Lerret NM, Rogozinska M, Jaramillo A, Marzo AL. Adoptive transfer of Mammaglobin-A epitope specific CD8 T cells combined with a single low dose of total body irradiation eradicates breast tumors. PLoS ONE 2012;7:e41240.
46. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002;17:19-29.
47. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007;30:1-15.